Vir Biotechnology: Funding, Investors & Team (Sep 2026)
Vir Biotechnology leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and the PRO-XTEN™ protease-releasable masking technology in infectious diseases and cancer, respectively. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with a leading program in chronic hepatitis delta, are complemented by strategic programs in oncology. We have broken ground in immunology, demonstrating our ability to discover, engineer and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients.
Vir Biotechnology has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vir Biotechnology Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Vir Biotechnology Funding Rounds
Vir Biotechnology Founders and Leadership Team
No contact details are on record for this team yet.
Vir Biotechnology Funding Compared to Other Biotechnology Startups
Vir Biotechnology's latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vir Biotechnology in Biotechnology and San Francisco
Companies Similar to Vir Biotechnology
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Vir Biotechnology Funding FAQs
What does Vir Biotechnology do?
Vir Biotechnology leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and the PRO-XTEN™ protease-releasable masking technology in infectious diseases and cancer, respectively. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with a leading program in chronic hepatitis delta, are complemented by strategic programs in oncology. We have broken ground in immunology, demonstrating our ability to discover, engineer and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients.
How much funding has Vir Biotechnology raised?
Vir Biotechnology has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Feb 2026.
When did Vir Biotechnology last raise funding?
Vir Biotechnology's most recent funding round on record is an undisclosed round of $150M, announced in Feb 2026.
Who founded Vir Biotechnology?
FundedIQ lists Klaus Frueh (Founder) at Vir Biotechnology.
Where is Vir Biotechnology headquartered?
Vir Biotechnology is based in San Francisco, California, United States.
How many employees does Vir Biotechnology have?
Vir Biotechnology is in the 251-500 employee band.
How does Vir Biotechnology's funding compare to other Biotechnology startups?
Vir Biotechnology's latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Vir Biotechnology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vir Biotechnology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.